Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

o conduct a small Phase Ib trial and a subsequent small Phase IIa trial of Atu027, as described below.  It would also enable the Company, and its Shareholders, to benefit from potential milestone payments which may arise from existing licensing agreements and licences which may arise from recently announced research collaborations including those with InteRNA Technologies BV and miRagen Inc.

If the Resolutions are not passed by Shareholders at the General Meeting, the Fundraising would be unable to proceed. In this situation, the Company would not have cash resources to maintain current operations beyond the second half of 2012 and would need to consider alternative strategic options that the Directors believe would not be in the best interests of Shareholders. These actions could include the sale of the business at a price which Directors believe would not recognise the potential long-term value of the business or possible insolvency.

It is the view of the Board that sale of the business in this circumstance would not enable Shareholders to benefit from the significant investment already made in developing the RNAi platform and Atu027 or the potentially significant value creation opportunity in RNAi therapeutics and in particular in Atu027 that would be afforded if sufficient finances were available.

Share Capital Reorganisation

Subject to the passing of Resolution 1 at the General Meeting, the Directors propose to sub-divide each Existing Ordinary Share of 1 pence in nominal value into one Sub-divided Share of 0.1 pence in nominal value and one Deferred Share of 0.9 pence in nominal value.  The Sub-divided Shares of 0.1 pence each so created will continue to carry the same rights as attach to the Existing Ordinary Shares of 1 pence each (save for the reduction in nominal value).  The Deferred Shares will be transferable only with the consent of the Company and will not be admitted to trading on AIM and will have the right
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Limited (ASX:NRT; NASDAQ: NVGN ) ("Company" or "Novogen"), ... entered into definitive agreements today to issue approximately ... 6-month option and half of one attaching 5-year ... investors in the United States ... proceeds of approximately AU$15,500,000 ("Placement"). The closing of ...
(Date:4/21/2015)... April 21, 2015 Progyny, Inc., the ... LLC, announced that it has secured additional capital from ... Biotech, SR One and Merck Serono Ventures. The funding ... patients the best fertility outcomes by aligning science, technology, ... online marketplace for families seeking fertility solutions and we ...
(Date:4/21/2015)... 21, 2015 Whether it’s used for troubleshooting ... bolted to a Kessler CineDrive in a cinematic ... beach, the TS3-H is designed to help any shooter create ... state-of-the-art 5MP sensor, the TS5-H offers the same convenient touchscreen ... characteristics. , According to Tom Boldt for Fastec, “We ...
(Date:4/20/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... commercializing proven cancer therapies in new orphan drug ... 106th Annual Meeting of the American Association ... the potential for its lead product candidate ...
Breaking Biology Technology:Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5
... processing revenues in the third, quarter of 2007 increased 25 percent ... ... Oct. 11 CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical ... revenues for the third quarter,of 2007 were approximately $21.9 million compared ...
... Challenges and Opportunities to Realize ... Critical Path Initiative Goals, ... PHST), a leading provider of software,strategic consulting, and regulatory services ... senior vice,president and chief technology officer, has been invited to ...
... Solstice Neurosciences, Inc.,("Solstice") announced the appointment of ... Smith will serve as Executive Chairman replacing James,Thomas, ... Chairman since Solstice,was founded in July 2004. ... expertise to Solstice that will be invaluable in ...
Cached Biology Technology:CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 3CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 4CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 5Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007 2Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007 3Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc. 2
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/18/2015)... SPRINGS, Florida , March 18, 2015 ... well as businesses, new revolutionary smart wallets and apps continue ... pace.  Companies currently entrenched in the mobile payment industry in ... Alibaba Group Holding Ltd. (NYSE: BABA ), Apple ... GOOG ) and Facebook Inc. (NASDAQ: FB ...
(Date:3/17/2015)... , March 17, 2015 Emotient, ... analytics software, today announced general availability of ... service for the analysis of facial expressions. The ... advertising, media content, products and services. It delivers ... engagement and sentiment - as derived from facial ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... your average persons idea of a good time, but for ... I think worms are totally cool, like humans only simpler ... working with the invertebrates is what will bring Dr. Fraser ... he will present some of his research findings in a ...
... ALBUQUERQUE, N.M. As Americans demand new and cleaner ... turning to algae as a promising new fuel source. ... nation,s reliance on imported oil while contributing to rural ... that algae-based biofuels could displace large volumes of diesel ...
... The American Association for Dental Research (AADR) has announced ... Chilton Fellowship in Clinical Research recipient. He will be ... Washington, DC, March 3, 2010. Currently, Dawson is ... the Delta Dental of Kentucky Clinical Research Center, in ...
Cached Biology News:The impact of genomics 2Fueling the future with fish tank residue: Sandia scientist discusses use of algae as a biofuel 2Fueling the future with fish tank residue: Sandia scientist discusses use of algae as a biofuel 3Fueling the future with fish tank residue: Sandia scientist discusses use of algae as a biofuel 4
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
... For use in hybridization incubators ... and GL 45 size PP plug-seal ... seal. Available in three lengths to ... plug-seal caps and O-rings available separately. ...
... gels The SpinPrep Gel DNA Kit enables efficient ... 12,000 bp in size from agarose gels. The procedure ... by adsorption of the DNA to a silica membrane ... the purified DNA is eluted in low-salt buffer. Each ...
Biology Products: